On Friday, RBC Capital maintained its Outperform rating and a $19.00 price target for R1 RCM Inc (NASDAQ:RCM), a leading provider of technology-enabled revenue cycle management services for healthcare providers. This affirmation comes in the wake of ongoing discussions about a potential take-private offer for the company.
The focal point of recent investor interest has been the impending take-private proposal by TowerBrook and Ascension. Earlier this month, on July 5, the joint venture indicated that its forthcoming bid would surpass the revised offer of $13.25 per share made by New Mountain Capital on July 1. Analysts at RBC Capital believe that a bid in the range of $14 to $15 per share may be necessary to appeal to R1 RCM's public shareholders.
Should the offer fall below this range, it is expected that it could at least establish a baseline value for the company's shares. However, it may also redirect investor attention back to the company's fundamental performance. R1 RCM is reportedly making good progress with its current implementations and optimizations, and RBC Capital expresses confidence in the company's potential for long-term earnings growth.
Nevertheless, there is an anticipation of a downward revision in the fiscal year 2024 guidance by approximately $25 to $30 million, which is attributed to the ramifications of a cyber-attack on Ascension, one of R1 RCM's major partners. Despite this, the firm's outlook on R1 RCM remains positive based on the company's operational advancements and earnings capabilities.
In other recent news, R1 RCM has reported Q1 revenues of $604 million and an adjusted EBITDA of $152 million, even with a cyberattack and a customer bankruptcy causing a $9.5 million dent in earnings. The company's updated outlook for 2024 anticipates revenue between $2.6 billion to $2.64 billion, and adjusted EBITDA between $625 million to $650 million.
Amidst acquisition buzz, TD Cowen has maintained a Buy rating on R1 RCM, while RBC Capital Markets reaffirmed an "Outperform" rating. On the other hand, KeyBanc Capital Markets downgraded the company to "Sector Weight" due to concerns related to the cyberattack. Citi Research upgraded R1 RCM to a "Buy" rating, hinting at a likely acquisition.
R1 RCM's tech transformation, including the integration of automation and AI, has been highlighted as a potential growth driver. These are recent developments that investors should consider.
InvestingPro Insights
R1 RCM Inc (NASDAQ:RCM) has been a subject of significant investor scrutiny amid potential take-private offers, drawing attention to its financial and market performance. According to InvestingPro data, RCM boasts a market capitalization of $5.41 billion, reflecting the scale of its operations in the healthcare technology sector. The company's revenue growth has been robust, with a 17.61% increase in the last twelve months as of Q1 2024, indicating a solid upward trajectory in its financial performance.
InvestingPro Tips suggest a mixed outlook with expectations of net income growth this year, despite not being profitable over the last twelve months. This aligns with the positive sentiment from RBC Capital regarding R1 RCM's long-term earnings growth potential. Additionally, a large price uptick of 28.92% over the last six months underscores the market's optimism about the company's prospects. For investors seeking more in-depth analysis, there are additional InvestingPro Tips available, which can be accessed with a subscription. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, and discover the full range of insights on R1 RCM.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.